Clinical trials: Immune Resistance
Type 1 Diabetes
Closed-Loop Glucagon Administration For Hypoglycemia Treatment
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers glucagon only can prevent or treat hypoglycemia vs. usual care for people with type 1 diabetes > 21 years old.
- Trial name
- NCT02181127
- Testing
- Glucagon-only Bionic Pancreas
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Corticosteroid-resistant or Relapsed ITP
Combination of Danazole With Berberine in the Treatment of ITP
A prospective, multicenter, open-label, Phase II, single arm, trial performed in 6 departments of hematology in China
- Trial name
- NCT03909763
- Testing
- Berberine plus danazol
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Peking University People's Hospital
Epilepsy, Cryptogenic, Epilepsy, Partial
IVIG Treatment for Refractory Immune-Related Adult Epilepsy
The purpose of the initial screening study is to find out if immune problems are an unrecognized cause of epilepsy in some patients.
- Conditions
- Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System
- Trial name
- NCT01545518
- Testing
- IVIG
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University
HIV Infections, AIDS
Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in HIV-infected patients with hypertriglyceridemia.
- Conditions
- HIV Infections, AIDS, Dyslipidemia, Hypertriglyceridemia
- Trial name
- NCT00346697
- Testing
- Omega-3 fatty acid administration
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Brown, Todd, M.D., Ph.D.
HIV Infections
A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults
The purpose of this study was to evaluate the efficacy of GSK3640254 + DTG relative to lamivudine (3TC) + DTG in treatment-naïve adult participants living with human immunodeficiency virus (HIV)-1.
- Trial name
- DYNAMIC (NCT04900038)
- Testing
- GSK3640254, Dolutegravir, Lamivudine capsules
- Where
- 44 sites in United States, Argentina and 8 more
- Volunteers
- 85 people
- Sponsor
- ViiV Healthcare
Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
- Trial name
- NCT05678998
- Testing
- WTX-330
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Werewolf Therapeutics, Inc.
HIV Infections
A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)
This study will investigate the safety and efficacy of raltegravir as a therapy for HIV-infected patients failing current therapy with 3-class antiviral resistance.
- Trial name
- NCT00293267
- Testing
- raltegravir potassium
- Volunteers
- 352 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV
Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.
The purpose of this study is to examine the safety, tolerability, and effectiveness of darunavir/ritonavir combined with TMC125 when current protease inhibitor(s), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI(s)) and…
- Trial name
- NCT00460746
- Testing
- TMC125, Darunavir; Ritonavir
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Tibotec, Inc
Type 1 Diabetes
Transdermal Basal Insulin Patch Study in Type 1 Diabetes
This study is designed to evaluate the pharmacokinetics/pharmacodynamics of an investigational basal insulin patch in type 1 diabetes patients.
- Trial name
- NCT00519623
- Testing
- PassPort(R) Transdermal Insulin Delivery System
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Altea Therapeutics
Multiple Myeloma
Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
The purpose of this study is to examine the effect of simvastatin and zoledronic acid on M-protein and/or free light chains when added to conventional chemotherapy for the treatment of multiple myeloma patients.
- Trial name
- NCT01772719
- Testing
- Simvastatin and zoledronic acid
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Louisville
Diabetes Mellitus Type 1
A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas
This study will test the hypothesis that a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults with type 1 diabetes.
- Trial name
- NCT02092220
- Testing
- Bionic Pancreas, Insulin pump with or without CGM
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Massachusetts General Hospital
Mitochondrial Diseases, Drug Resistant Epilepsy
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome
- Trial name
- MIT-E (NCT04378075)
- Testing
- Vatiquinone
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 68 people
- Sponsor
- PTC Therapeutics
Type 1 Diabetes Mellitus, Autoimmune Diabetes
Medtronic Minimed Overnight Closed-Loop System
To test the function and safety of the Medtronic Overnight Closed Loop (OCL) System in a closely monitored 12 hour overnight inpatient study.
- Conditions
- Type 1 Diabetes Mellitus, Autoimmune Diabetes, Juvenile-Onset Diabetes, Diabetes, Mellitus, Type 1
- Trial name
- NCT01881009
- Testing
- Hybrid Closed-loop System, Sensor-augmented pump
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Bruce A. Buckingham
Multiple Myeloma
Fluoroquinolone Resistance Prevalence Study
This is an exploratory study to determine the prevalence of fluoroquinolone resistance in patients receiving dose-intense melphalan with autologous peripheral blood stem cell (PBSC) transplantation in the treatment of multiple…
- Trial name
- FRE (NCT05824689)
- Where
- 2 sites in United States
- Volunteers
- 124 people
- Sponsor
- Hackensack Meridian Health
Infection, Human Immunodeficiency Virus
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
This 48 week, phase 2b study in 150 HIV-1 infected antiretroviral therapy experienced adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of…
- Trial name
- SONNET (NCT01199731)
- Testing
- GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine
- Where
- 41 sites in United States, Belgium and 3 more
- Volunteers
- 30 people
- Sponsor
- ViiV Healthcare
HIV Infections
Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine
Dolutegravir (DTG) plus lamivudine (3TC) is a dual regimen combination recommended for both naïve and suppressed persons with HIV-1 infection1.
- Trial name
- VOLVER (NCT04880785)
- Testing
- Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]
- Where
- 17 sites in Spain
- Volunteers
- 167 people
- Sponsor
- Fundacion SEIMC-GESIDA
Ovarian Cancer
A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer
To evaluate the efficacy and safety of anti-PD-1 antibody MK-3475 (pembrolizumab) in combination with gemcitabine and cisplatin chemotherapy in women with recurrent platinum-resistant ovarian cancer.
- Trial name
- PemCiGem (NCT02608684)
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Cedars-Sinai Medical Center
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
This study will assess the pharmacokinetics of nilotinib in Ph+ CML pediatric patients that are newly diagnosed or resistant or intolerant to imatinib or dasatinib or refractory or relapsed Ph+ ALL compared to the adult…
- Trial name
- NCT01077544
- Testing
- Nilotinib
- Where
- 12 sites in France, Italy and 2 more
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Human Immunodeficiency Virus (HIV), Vitamin D Deficiency
Study of Vitamin D and Effect on Heart Disease and Insulin Resistance
The purpose of this study is to evaluate how Vitamin D affects endothelial function, inflammation, lipids, insulin resistance, vitamin D levels, and parathyroid hormone (PTH).
- Conditions
- Human Immunodeficiency Virus (HIV), Vitamin D Deficiency, HIV Infections
- Trial name
- NCT01093417
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University Hospitals Cleveland Medical Center
Prostate Cancer, Recurrent Prostate Carcinoma
Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
This phase II trial studies how well nivolumab and ipilimumab work in treating patients with hormone-resistant prostate cancer that has spread to other places in the body and express androgen receptor-variant-7 (AR-V7).
- Conditions
- Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
- Trial name
- STARVE-PC (NCT02601014)
- Testing
- Ipilimumab, Nivolumab, Enzalutamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins